Management factors contributing to delays in cancer drug registration in South Africa

dc.contributor.authorShai, Mmatsela Lorraine
dc.date.accessioned2024-08-12T12:01:24Z
dc.date.available2024-08-12T12:01:24Z
dc.date.issued2022
dc.descriptionA research report submitted in partial fulfillment of the requirements for the degree of Master of Business Administration to the Faculty of Commerce, Law and Management, Wits Business School, University of the Witwatersrand, Johannesburg, 2022
dc.description.abstractOne of the leading causes of sickness and early death worldwide is cancer.The cancer mortality is especially high in low and middle-income countries (LMICs). The National Medicines Regulatory Authorities (NMRAs) play an important role to ensure that drugs meet the quality, safety, and efficacy requirements made available to patients. The National regulatory authorities are also accountable for enforcing regulatory demands promptly andensuring that patients have timely access to drugs. Delays in the registration of cancer drugs will have an adverse impact on cancer patients such as poor quality of life and early death. Section 27 of the Constitution of South Africa guarantees the right to have access to health care service. The study aims to determine management factors that contribute to delays in the registration of cancer drugs. As a result, the research contributes to the theoretical body of knowledge. The study took a qualitative approach by sending out an interview schedule to 10 South African pharmaceutical companies for self-completion. Several methods were considered in determining a suitable study strategy, study design, research approach, and self-administered interview questions. These methods were implemented in order to achieve the study’s objectives. This served as a primary source of information. The interview questions were completed and uploaded for analysis using the Qualtrics XM tool. The information that was gathered showed that all of the participants have to deal with the problem of registration delays for cancer drugs. The findings could help to clarify the overall critical factors, their impact, and the relationship between the key factors and stakeholders involved in cancer drug registration. The uniqueness of this research lies in the results provided by different participants from the pharmaceutical industry and in evaluating their perspectives on these delays. The research adds significant value through its evidence based on the responses received
dc.description.submitterMM2024
dc.facultyFaculty of Commerce, Law and Management
dc.identifier.citationShai, Mmatsela Lorraine. (2022). Management factors contributing to delays in cancer drug registration in South Africa [Master’s dissertation, University of the Witwatersrand, Johannesburg]. WireDSpace.
dc.identifier.urihttps://hdl.handle.net/10539/40065
dc.language.isoen
dc.publisherUniversity of the Witwatersrand, Johannesburg
dc.rights© 2022 University of the Witwatersrand, Johannesburg. All rights reserved. The copyright in this work vests in the University of the Witwatersrand, Johannesburg. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of University of the Witwatersrand, Johannesburg.
dc.rights.holderUniversity of the Witwatersrand, Johannesburg Citation
dc.schoolWITS Business School
dc.subjectManagement factors
dc.subjectDelays
dc.subjectCancer
dc.subjectRegistration
dc.subjectDrug application
dc.subjectRegulators
dc.subjectPharmaceutical Companies.
dc.subjectUCTD
dc.subject.otherSDG-8: Decent work and economic growth
dc.titleManagement factors contributing to delays in cancer drug registration in South Africa
dc.typeDissertation

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Shai_Management_2024.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Thumbnail Image
Name:
Shai_Management_2024.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.43 KB
Format:
Item-specific license agreed upon to submission
Description: